MedTrace Logo

Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation

NCT03929718 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-29

No results posted yet for this study

Summary

The purpose of this study is to accurately determine, using an implantable rhythm monitor, the long-term incidence of new atrial fibrillation after ablation of atrial flutter in those treated with spironolactone compared with standard medical therapy.

Conditions

  • AFib

Interventions

DRUG

Spironolactone

receive spironolactone treatment after CTI ablation

DRUG

No Spironolactone

no spironolactone treatment

Sponsors & Collaborators

  • Piedmont Healthcare

    lead OTHER

Principal Investigators

  • Bruce Stambler, MD · Piedmont Healthcare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-24
Primary Completion
2025-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03929718 on ClinicalTrials.gov